However, 70% of breast cancer diagnoses are ER/PR+ (collectively referred to as hormone receptor positive, HR+), thus understanding the TIME of these tumors is of clinical importance (Goldberg et al., 2021). The gene discussed is ESR1; the disease is breast carcinoma.